Trial Profile
An Open-Label Multicenter Phase 1 Study of E7046 in Subjects With Selected Advanced Malignancies
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2022
Price :
$35
*
At a glance
- Drugs Palupiprant (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Cervical cancer; Colorectal cancer; Head and neck cancer; Liver cancer; Male breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors Eisai Inc
- 27 Sep 2022 Results (n=48) of Population pharmacokinetic analysis( from two phase 1 studies NCT02540291 and NCT03152370) to characterize the pharmacokinetic profle of orally administered AN0025 after single and multipledoses in cancer patients presented at the 2022 American College of Clinical Pharmacology Annual Meeting
- 30 Jul 2018 Status changed from recruiting to discontinued.
- 12 Sep 2017 Results (n=30) presented at the 42nd European Society for Medical Oncology Congress